Table 1.

Baseline characteristics of participants at randomization

CharacteristicsPlacebo (n=27)Losartan (n=26)Spironolactone (n=27)
Men (%)445048
African American (%)373126
Hispanic (%)444663
Age (yr)49.3 (±8.8)52.3 (±9.1)51.7 (±9.3)
Duration of diabetes (yr)14.4 (±9.6)17.0 (±7.7)17.0 (±9.1)
24-h ambulatory systolic BP (mmHg)138 (±15)143 (±15)135 (±11)
24-h ambulatory diastolic BP (mmHg)75 (±9)75 (±9)71 (±9)
Serum creatinine (mg/dl)1.4 (±0.7)1.7 (±0.7)1.8 (±0.9)
Urine albumin to creatinine ratio (mg/g)917 (633 to 1329)897 (611 to 1316)1094 (758 to 1579)
Hemoglobin A1c (%)8.1 (±1.3)7.6 (±1.3)7.4 (±1.6)
Antihypertensive regimens at randomization
 Diuretic (% taking)85.588.596.3
 β-Blocker70.463.477.8
 α-Blocker29.630.825.9
 Central adrenergic antagonist7.411.511.1
 Vasodilator3.700
 Three or more drugs (%)596548
  • Data are listed as mean (SD) or geometric mean (95% confidence interval). There were no statistically significant between-group differences.